PF-Atlas › Clinical Trials › NCT00352482

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

Sildenafil · Phase 2

Registry ID
NCT00352482
Phase
Phase 2
Status
Completed
Drug / intervention
Sildenafil (50 mg)
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Start
2004-11
Enrollment
20
Locations
1

About this trial

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. Currently, no medications can reverse the damage to the lungs caused by IPF, but individuals are encouraged to engage in moderate exercise to strengthen lung function. This study will evaluate the effectiveness of sildenafil at improving exercise tolerance and breathing difficulties in individuals with IPF.

View NCT00352482 on ClinicalTrials.gov →

Explore related

All Sildenafil trialsAll IPF trials

Related trials

sildenafil — NCT00359736sildenafil — NCT00659529Sildenafil — NCT01194232Sildenafil — NCT02057458Sildenafil — NCT00981747sildenafil — NCT02626182
Medical disclaimer. This page summarizes public trial data for NCT00352482 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.